BridgeBio Oncology Therapeutics
South San Francisco, California, United States · Biopharma, Biotechnology, Health Care
BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company, focuses on RAS-pathway malignancies, specifically developing therapies for patients with KRASG12C mutations. Their lead candidate, BBO-8520, is a first-in-class dual inhibitor targeting both active and inactive forms of KRASG12C, demonstrating significant preclinical efficacy. The company aims to overcome adaptive resista
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 62
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (BBOT)
- Website
- bridgebiooncology.com
Recent activity at BridgeBio Oncology Therapeutics
- : SEC 8-K (8.01): On September 8, 2026, BridgeBio Oncology Therapeutics, Inc. announced new data regarding their drug candidate BBO-8520, focusing on its application in second-line plus non-small cell lung cancer (NSCLC) in combination therapies, particularly targeting KRAS-mutant cancers. The announcement included a press release and an updated corporate presentation, which reflects the company's strategic focus and recent developments. This update aims to communicate important advancements in their product pipeline to stakeholders. The press release is attached as Exhibit 99.1, and the revised corporate presentation as Exhibit 99.2.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On April 27, 2026, BridgeBio Oncology Therapeutics, Inc. reported the departure of Eli Wallace, Ph.D. from the Board of Directors, a decision effective April 20, 2026. He was succeeded by Pedro J. Beltran, Ph.D., who also assumed the role of President and Chief Executive Officer. Following his resignation, the Company entered into a Consulting Agreement with Dr. Wallace to provide advisory services related to research and development, effective retroactively from April 21, 2026, lasting for 12 months. Dr. Wallace's compensation will include the continued vesting of his equity awards, and he is entitled to severance benefits as a Tier 1 officer, given his termination was not for cause. This significant leadership change impacts the strategic direction of the company, particularly regarding ongoing projects in development.
- : SEC 8-K (5.02): On April 20, 2026, BridgeBio Oncology Therapeutics, Inc. appointed Pedro Beltran, Ph.D., as the new President and Chief Executive Officer, succeeding Eli Wallace, Ph.D., who resigned from the CEO position and the Board of Directors effective immediately. Dr. Beltran, 55, previously served as the Chief Scientific Officer and has a substantial background in oncology research. His employment agreement includes an annual base salary, target bonus, equity awards eligibility, and severance benefits as a Tier 1 officer under the Executive Severance Plan. Dr. Wallace's resignation was amicable, with his continuing role as an advisor to the company, marking a significant leadership transition for the firm.
- : BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran as CEO and Idan Elmelech as COO
- : SEC 8-K (5.02): On March 24, 2026, BridgeBio Oncology Therapeutics, Inc. appointed Peter Lebowitz, M.D., Ph.D. as a director to fill a vacancy on the Board following an increase in its size to nine members. Dr. Lebowitz will serve as a Class I director until the 2026 annual meeting of stockholders. He is also appointed to the Nominating and Corporate Governance Committee and the Compensation Committee, effective immediately. As part of his compensation, he will receive a one-time nonqualified stock option to purchase 63,350 shares of common stock at an exercise price of $8.72 per share based on the market price on the day of his appointment. The company has undertaken to indemnify Dr. Lebowitz against certain expenses arising from his service as a member of the Board.
- : SEC 8-K (8.01): On January 7, 2026, BridgeBio Oncology Therapeutics, Inc. released a press release detailing new clinical data that advances its portfolio consisting of three innovative and differentiated RAS and PI3K α pipeline programs. This significant event implies progress in their research and development efforts, potentially impacting their market position and attracting investor interest. The event showcases the company's commitment to advancing its therapeutic offerings amidst competitive market conditions, reflecting strategic growth in their oncology-focused business.
- : SEC 8-K (8.01): On January 7, 2026, BridgeBio Oncology Therapeutics, Inc. announced new clinical data advancing its portfolio of three innovative and differentiated RAS and PI3K α pipeline programs. This press release indicates significant advancements in their drug development efforts, potentially impacting their market position and future revenue. The specific programs highlighted in the announcement may present new opportunities for the company in oncology, reflecting ongoing innovation and investment in their research initiatives.
- : BridgeBio Oncology Therapeutics Publishes Preclinical Data on First-in-Class BBO-8520 Molecule for KRASG12C Mutant Tumors.
Leadership
- Daniel Watson, SVP, Head of CMC
- John Sakkis, Talent Acquisition Leader
- Idan Elmelech, Chief Operating Officer
- Pedro J. Beltran, PhD, Chief Executive Officer
Verified email and direct lines for BridgeBio Oncology Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
BridgeBio Oncology Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
BridgeBio Oncology Therapeutics in the news
- BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer - BioSpace (Jan 09, 2025)
- BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive (Feb 28, 2025)
- BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public - The Business Journals (Feb 28, 2025)
- BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II To Merge - citybiz (Feb 28, 2025)
- BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire (Feb 28, 2025)
- BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - BioSpace (Nov 18, 2024)
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) - GlobeNewswire (May 02, 2024)
- BridgeBio spinout launches with $200M for KRAS cancer drugs - BioPharma Dive (May 02, 2024)
Companies similar to BridgeBio Oncology Therapeutics
- Zai Lab Limited & MediLink Therapeutics (Suzhou) Ltd · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- TORL BioTherapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Abivax · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Apollomics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Day One Biopharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About BridgeBio Oncology Therapeutics: questions and answers
What does BridgeBio Oncology Therapeutics do?
BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company, focuses on RAS-pathway malignancies, specifically developing therapies for patients with KRASG12C mutations. Their lead candidate, BBO-8520, is a first-in-class dual inhibitor targeting both active and inactive forms of KRASG12C, demonstrating significant preclinical efficacy. The company aims to overcome adaptive resista
Where is BridgeBio Oncology Therapeutics headquartered?
BridgeBio Oncology Therapeutics is headquartered in South San Francisco, California, United States.
How many employees does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has about 62 employees.
Who leads BridgeBio Oncology Therapeutics?
Pedro J. Beltran, PhD is a Chief Executive Officer at BridgeBio Oncology Therapeutics.
What is the latest news on BridgeBio Oncology Therapeutics?
On Sep 08, 2026, SEC 8-K (8.01): On September 8, 2026, BridgeBio Oncology Therapeutics, Inc. announced new data regarding their drug candidate BBO-8520, focusing on its application in second-line plus non-small cell lung cancer (NSCLC) in combination therapies, particularly targeting KRAS-mutant cancers. The announc
Is BridgeBio Oncology Therapeutics a public company?
Yes. BridgeBio Oncology Therapeutics is publicly traded under the ticker BBOT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy